[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Huilun Pharmaceutical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":96},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053591","phase-2-evaluate-the-safety-and-efficacy-of-hl-1186-tablet-for-postoperative-analgesia-in-orthopedic-surgery-100053591",false,"NCT07699601","Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Analgesia in Orthopedic Surgery","A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Parallel-Group Phase II\u002FIII Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablets for Postoperative Analgesia in Orthopedic Surgery","Inclusion Criteria:\n\n1. 18 years old ≤ age ≤ 75 years old, gender is not limited.\n2. 18 kg\u002Fm2 ≤ Body Mass Index (BMI) ≤ 30kg\u002Fm2.\n3. Scheduled to undergo orthopedic surgery under general anesthesia, with expected moderate-to-severe postoperative pain intensity.\n4. Able to understand the research process and the use of pain scales, and communicate effectively with researchers.\n5. After surgery completion, the participant is judged by the investigator to be awake and has a resting NRS score ≥ 4.\n\nExclusion Criteria:\n\n1. Previous surgery on the same site that may affect pain perception at the surgical site.\n2. Paresthesia or other pain that may affect postoperative pain evaluation or scale assessment.\n3. Neuropsychological disorders that may affect postoperative pain evaluation or scale assessment.\n4. Unstable angina, myocardial infarction, severe arrhythmia, NYHA cardiac function class ≥ III, or recurrent asthma attacks, etc., deemed unsuitable for inclusion by the investigator.\n5. Poorly controlled hypertension.\n6. Sleep apnea syndrome, or the presence of a difficult airway as assessed by the investigator.\n7. Known allergy to any component of the investigational drug(s), to perioperative (from induction of anesthesia to completion of surgery) anesthetic\u002Fanalgesic\u002Fantiemetic drugs, or a history of allergy to ≥ 3 substances.\n8. Positive for human immunodeficiency virus (HIV) antibody; positive for Treponema pallidum antibody and positive toluidine red unheated serum test (TRUST); positive for hepatitis B surface antigen (HBsAg) with detectable HBV-DNA; or positive for hepatitis C virus (HCV) antibody.\n9. Women who are pregnant or breastfeeding (within 1 year after delivery).\n10. Participation in another drug or medical device trial within 1 month before screening, or currently participating in another clinical trial receiving investigational intervention.\n11. Any other condition considered unsuitable for participation by the investigator.","ALL","18 Years","75 Years",{"count":20,"type":21},330,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","This clinical trial is a multiple-center, randomized, double-blind, placebo- and active-controlled parallel-group Phase II\u002FIII clinical trial, to evaluate the efficacy and safety of HL-1186 Tablets for Postoperative Analgesia in Orthopedic Surgery.",[28],"Postoperative Pain","RECRUITING","2026-07-08",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":33},"2026-05-09",{"date":37,"type":21},"2026-12",{"name":39,"class":40},"Shanghai Huilun Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":50,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100604197","phase-3-a-phase-iii-clinical-study-of-h077-sustained-release-tablets-compared-with-silodosin-capsules-in-the-treatment-of-benign-prostatic-hyperplasia-100604197","NCT07146386","A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia","A Randomized, Double-blind, Controlled, Non-inferiority Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of H077 Sustained-release Tablets Versus Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n1. Male, aged 50 to 75 years old, inclusive of both endpoints;\n2. Meets the clinical diagnostic criteria for benign prostatic hyperplasia (BPH);\n3. IPSS score was ≥ 8 points, and the QOL score was ≥ 3 points during the screening period;\n4. Prostate volume ≥ 20 ml (measured by transabdominal ultrasound);\n5. PSA≤4 ng\u002FmL;\n6. During the screening period, Qmax \\> 5 ml\u002Fs and Qmax \\\u003C15 ml\u002Fs (urine output ≥ 125 ml);\n7. The subjects had no intention of having children from the screening stage until 6 months after the last administration of the drug, and they were able to take effective contraceptive measures;\n8. Understand and voluntarily sign the written informed consent form (ICF), and be willing and capable of undergoing regular visits, treatment plans, laboratory tests, and other trial procedures.\n\nExclusion Criteria:\n\n1. Those who are allergic to any component of α\u002Fβ-adrenergic receptor blockers or the test drugs; or who have contraindications;\n2. History or evidence of prostate cancer (such as positive biopsy or ultrasound result, suspicious DRE findings), excluding patients who had suspicious ultrasound or DRE findings within 6 months prior to the screening but had negative biopsy results and stable PSA levels;\n3. During the screening process, researchers identified patients with BPH who required minimally invasive prostate treatment or surgical intervention;\n4. Has previously undergone prostate surgery, including open prostate surgery, transurethral minimally invasive prostate surgery, balloon dilation or stent replacement, or other invasive measures for treating BPH;\n5. Subjects with residual urine volume greater than 100 mL (measured by transabdominal ultrasound) or those for whom catheterization is deemed necessary by the investigator;\n6. Subjects who underwent cystoscopy, other transurethral endoscopic procedures, or therapeutic urinary catheterization within 1 month prior to the screening period;\n7. Subjects with a history of acute urinary retention (AUR) or cystostomy within 3 months prior to the screening period;\n8. Subjects with documented pelvic cavity trauma or urethral surgical interventions;\n9. During the screening period, any disease other than BPH that the investigator deems could cause urinary symptoms or changes in urine flow rate (such as neurogenic bladder, bladder neck fibrosis, bladder tumor, urinary calculi, urethral stricture, phimosis or penile tumor, acute or chronic prostatitis, acute or chronic urinary tract infection, acute or chronic renal failure, congenital developmental abnormalities of the urinary and reproductive system, etc.) must be excluded;\n10. During the screening period, subjects with positive hepatitis B surface antigen (HBsAg) and HBV-DNA levels greater than 500 IU\u002Fml, or with positive hepatitis C virus antibody (HCV-Ab) and HCV-RNA levels greater than 500 IU\u002Fml, or who had received hepatitis-related antiviral drug treatment within 6 months prior to the first administration;\n11. During screening period, the levels of aspartate transaminase (AST) or alanine transaminase (ALT) were more than 3 times the upper limit of the normal range;\n12. During the screening period, serum creatinine was greater than 1.5 times the upper limit of the normal range;\n13. Patients who plan to undergo cataract surgery during the medication period and within 3 months after the medication is completed;\n14. Currently or previously have the following diseases or conditions: a) Have a clear history of orthostatic hypotension in the past, or have a positive orthostatic hypotension test; or have a history of malignant hypertension; b) Have recurrent dizziness, vertigo, loss of consciousness or syncope, or any other signs or symptoms that the investigator considers may be worsened by celerodisonic; c) Have undergone major surgery (excluding biopsy) within 4 weeks before screening and have not fully recovered; d) Have had myocardial infarction, unstable angina pectoris, need for clinical intervention or clinical symptoms of arrhythmia, need for clinical intervention or clinical symptoms of congestive heart failure, or any cerebrovascular accident within 6 months before screening; e) Have a previous surgical history or have severe gastrointestinal diseases, which the investigator considers may affect the absorption, distribution, metabolism, etc. of the study drug; f) Have active infectious diseases and require systemic anti-infection treatment; g) Have a history of diabetes and poor blood sugar control, or have patients with diabetic nephropathy that require drug control; h) Have had malignant tumors within 5 years before screening; i) Have patients with other serious primary diseases and functional disorders in the heart, brain, lungs, liver, kidneys, hematopoietic system, endocrine system, etc;\n15. Currently or previously used the following drugs: a) Within 3 months before screening or during the study, need to use 5α-reductase inhibitors, anti-androgen drugs, and androgen drugs or any other drugs that affect hormone levels or prostate volume; b) Within 2 weeks before screening or during the study, need to use any α-adrenergic receptor blockers or any α-receptor blockers other than cilorodin during the study; c) Within 4 weeks before screening or during the study, need to use PDE-5 inhibitors, anticholinergic drugs, anticholinergic drugs or any other drugs that affect urinary function; d) Within 2 weeks before screening or during the study, need to use traditional Chinese medicine, Chinese herbs, or botanical preparations with indications for BPH; e) Within 4 weeks before screening or during the study, need to use any CYP3A4 strong inhibitors, CYP3A4 strong inducers or P-gp strong inhibitors;\n16. Subjects who participated in other drug or device clinical trials within 3 months prior to screening;\n17. Subjects with current alcohol or substance abuse were excluded;\n18. The researchers determined that the patient had other circumstances that affected the safety or efficacy assessment of the study drug, the obtaining of informed consent, or the compliance with the study procedures.","MALE","50 Years",{"count":52,"type":21},728,[25],"This is a randomized, double-blind, controlled, non-inferiority multicenter Phase III clinical study to evaluate the efficacy and safety of H077 sustained-release tablets versus silodosin capsules in treating benign prostatic hyperplasia.",[56,57],"Benign Prostatic Hyperplasia","Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms",[59,60,61,62,63],"Benign prostatic hyperplasia","lower urinary tract symptoms","Silodosin","selective α1A-adrenergic receptor blocker","IPSS scores","NOT_YET_RECRUITING","2025-08-22",{"date":67,"type":33},"2025-08-28",{"date":69,"type":21},"2025-08",{"date":71,"type":21},"2027-03",{"name":39,"class":40},66,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100589780","phase-2-a-clinical-study-to-evaluate-the-efficacy-safety-pharmacokinetics-and-pharmacodynamics-of-inhaled-h057-in-the-treatment-of-acute-exacerbations-of-bronchiectasis-100589780","NCT06958861","A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis","Inclusion Criteria:\n\nSubjects must meet all of the following criteria to be eligible for enrollment in this study:\n\n1. Age ≥18 years, regardless of gender;\n2. Patients who are determined by the investigator to be in an acute exacerbation phase of bronchiectasis prior to enrollment: at least three out of the following six symptoms-cough, changes in sputum volume, purulent sputum, dyspnea or reduced exercise tolerance, fatigue or malaise, hemoptysis-have worsened for more than 48 hours, and the clinician deems that intervention is necessary;\n3. Able to tolerate nebulized inhalation treatment;\n4. After instruction, able to correctly use the nebulizer for treatment and accurately complete questionnaires;\n5. Subjects must fully understand the purpose, nature, methods, and potential adverse events of the trial, voluntarily agree to participate, and sign the informed consent form, or have a legally authorized representative provide informed consent on their behalf.\n\nExclusion Criteria:\n\nIf a subject meets any of the following criteria, they are not eligible to participate in this study:\n\n1. Patients with bronchiectasis caused by cystic fibrosis, as determined by the investigator;\n2. Patients who have experienced an acute exacerbation of bronchiectasis for more than 7 days;\n3. Patients with an acute exacerbation of bronchiectasis who have received intravenous antibiotic treatment for more than 72 hours prior to enrollment;\n4. Patients with mild bronchiectasis caused by asthma;\n5. Patients with comorbid allergic bronchopulmonary aspergillosis, active tuberculosis, or active non-tuberculous mycobacterial infection requiring standardized treatment;\n6. Patients with moderate or massive hemoptysis during an acute exacerbation of bronchiectasis (moderate hemoptysis: 100-500 mL within 24 hours; massive hemoptysis: \\>500 mL within 24 hours or a single episode of 100-500 mL);\n7. Patients with significant liver or kidney dysfunction (ALT, AST \\>2 times the upper limit of normal \\[ULN\\]; Cr \\>1.5 times ULN);\n8. Patients with a history of malignancy or who have achieved clinical remission for less than 5 years;\n9. Patients with any other unstable clinical conditions deemed significant by the investigator, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physiological dysfunction, and: a) Whose condition may affect the patient's safety during the study; b) That may impact the study results and their interpretation; c) That may hinder the patient's ability to complete the entire study;\n10. Patients who are positive for hepatitis B surface antigen (HBsAg) with HBV-DNA \\>1000 copies\u002FmL or 200 IU\u002FmL, or positive for hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or anti-Treponema pallidum antibody;\n11. Patients who are allergic to the active ingredients or excipients of the investigational product or who have a history of hypersensitivity or an allergic constitution;\n12. Patients who have participated in other drug or medical device trials within the past 3 months or are currently participating in another clinical trial;\n13. Pregnant women, lactating women, and women of childbearing potential;\n14. Subjects whom the investigator considers unsuitable for participation in this study for any reason.",{"count":82,"type":21},180,[24],"This is a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of inhaled H057 in the treatment of acute exacerbations of bronchiectasis.",[86],"Acute Exacerbations of Bronchiectasis","2025-05-06",{"date":89,"type":33},"2025-05-09",{"date":91,"type":21},"2025-05",{"date":93,"type":21},"2027-05",{"name":39,"class":40},19,""]